Press Release

' GRANULES Date: November02, 2026 National StockExchangeofIndiaLimited BSE Limited Symbol: NSE: GRANULES: BSE: 532482 Dear Sir, Sub' PressReleaseto theAnalysts/Investors We refer to the unaudited financial results for the second quarter and half-year ended September 30, 2026, submitted to you today, i.e., November 02, 2026. We are now enclosing the press release inthis regardtotheAnalysts/Investors. This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly takethe above information Ollrecord. For GRANULES INDIALIMITED Cl-lAITANYATUMMALA (COMPANYSECRETARY& O COMPLIANCE OFFICER) I*PoERp¥*J REGISTEREDOFFICE GranulesIndiaLimited CIN:L2l+110TG1991PLC012Li71 15*'"Floor,GranulesTower, BotanicalGardenRoad, Kondapur,Hyderabad_500084,Telangana, India ContactUS:Tel:+91 4069043500 | FaX:+91-40-23115145 | maiI@granulesindia.com www,granulesindla.com Press Release for Immediate Release Q2FY27 Revenue from operations at INR 15,600 Mn up 20% YoY, EBITDA at INR 3,376 Mn up 21% YoY, PBT at INR 2,434 Mn up 38% YoY, PAT at INR 1,818 Mn up 39% YoY. Hyderabad, India, November 2, 2026: G ranules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended September 30, 2026. Financial Summary (All numbers in INR Mn) QUARTERLY CONSOLIDATED Growth Growth Q2FY27 Q1FY27 Q2FY26 FINANCIALS (QoQ) (YoY) Revenue from Operations 15,600 14,768 6% 12,970 20% EBITDA 3,376 3,389 0% 2,782 21% EBITDA % 22% 23% 21% PBT 2,434 2,404 1% 1,759 38% PAT 1,818 1,800 1% 1,306 39% PAT % 12% 12% 10% Financial and Business Summary for Q2FY27 ▪ Revenue from Operations of Q2FY27 stood at INR 15,600 Mn, a growth of 20% YoY, Revenue share from the North America is 72% in Q2FY27 as compared to 76% in Q2FY26 and from the Europe is 16% in Q2FY27 as compared to 12% in Q2FY26. ▪ Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides CDMO contribute 73%, 13%, 10% and 3% of revenue from operations respectively for Q2FY27. ▪ ROCE is at 17.6% in Q2FY27 in par with FY26. ▪ Closed the quarter with a net cash position of ₹8,280 million, compared with net debt of ₹1,012 million in Q1 FY27. Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “Our Quarterly revenue has crossed ₹1500 Cr in Q2 FY27 with EBITDA of ₹338 Cr, despite higher input and logistics costs from tensions in West Asia. Cost pressures will persist and we are working with customers to manage them with a lag. We filed two potential first-to-file ANDAs in H1, which makes it a total of three potential first to file ANDAs and continue to shift towards complex generics and peptide CDMO. With the balance warrant proceeds received, we hold net cash of ₹828 Cr to invest in R&D, manufacturing and quality”. “We recently concluded a US FDA audit at the Gagillapur site, The inspection progressed constructively and the observations are of a nature that we believe can be fully addressed through our responses and corrective and preventive actions and we will continue to engage transparently with the agency.” About Granules India Ltd. (BSE: 532482, NSE: GRANULES) Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 7 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL. Safe Harbor This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaim any such obligation to, update or alter its forward- looking statements, whether as a result of new information, future events, or otherwise. Contacts: Granules IR Desk Chaitanya Tummala investorrelations@granulesindia.com Company Secretary chaitanya.tummala@granulesindia.com